%0 Journal Article
%@ 2291-5222
%I JMIR Publications
%V 10
%N 5
%P e34017
%T German Mobile Apps for Patients With Psoriasis: Systematic Search and Evaluation
%A Lull,Christian
%A von Ahnen,Jan Alwin
%A Gross,Georg
%A Olsavszky,Victor
%A Knitza,Johannes
%A Leipe,Jan
%A Schmieder,Astrid
%+ Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Josef-Schneider-Strasse 2, Würzburg, 97080, Germany, 49 0931 201 26351, astrid.schmieder@umm.de
%K psoriasis
%K eHealth
%K mHealth
%K telemedicine
%K teledermatology
%K disease management
%K smartphone application
%K mental health
%K mobile health
%K health app
%K dermatology
%K skin
%D 2022
%7 26.5.2022
%9 Original Paper
%J JMIR Mhealth Uhealth
%G English
%X Background: Psoriasis is a chronic inflammatory skin disease. The visibility of erythematous plaques on the skin as well as the pain and itchiness caused by the skin lesions frequently leads to psychological distress in patients. Smartphone apps are widespread and easily accessible. Earlier studies have shown that apps can effectively complement current management strategies for patients with psoriasis. However, no analysis of such apps has been published to date. Objective: The aim of this study is to systematically identify and objectively assess the quality of current publicly available German apps for patients with psoriasis using the Mobile Application Rating Scale (MARS) and compile brief ready-to-use app descriptions. Methods: We conducted a systematic search and assessment of German apps for patients with psoriasis available in the Google Play Store and Apple App Store. The identified apps were randomly assigned to 1 of 3 reviewers, who independently rated them using the German MARS (MARS-G). The MARS-G includes 15 items from 4 different sections (engagement, functionality, aesthetics, and information) to create an overall mean score for every app. Scores can range from 1 for the lowest-quality apps to 5 for the highest-quality apps. Apps were ranked according to their mean MARS-G rating, and the highest-ranked app was evaluated independently by 2 patients with psoriasis using the user version of the MARS-G (uMARS-G). Furthermore, app information, including origin, main function, and technical aspects, was compiled into a brief overview. Results: In total, we were able to identify 95 unique apps for psoriasis, of which 15 were available in both app stores. Of these apps, 5 were not specifically intended for patients with psoriasis, 1 was designed for clinical trials only, and 1 was no longer available at the time the evaluation process began. Consequently, the remaining 8 apps were included in the final evaluation. The mean MARS-G scores ranged from 3.51 to 4.18. The app with the highest mean MARS-G score was Psoriasis Helferin (4.18/5.00). When rated by patients, however, the app was rated lower in all subcategories, resulting in a mean uMARS-G score of 3.48. Most apps had a commercial background and a focus on symptom tracking. However, only a fraction of the apps assessed used validated instruments to measure the user’s disease activity. Conclusions: App quality was heterogeneous, and only a minority of the identified apps were available in both app stores. When evaluated by patients, app ratings were lower than when evaluated by health care professionals. This discrepancy highlights the importance of involving patients when developing and evaluating health-related apps as the factors that make an app appealing to users may differ between these 2 groups. Trial Registration: Deutsches Register Klinischer Studien DRKS00020963; https://tinyurl.com/ye98an5b 
%M 35617014
%R 10.2196/34017
%U https://mhealth.jmir.org/2022/5/e34017
%U https://doi.org/10.2196/34017
%U http://www.ncbi.nlm.nih.gov/pubmed/35617014